Ekso Bionics removes $6.75 floor from ATM offering; shareholders approve share plan increase

EKSO BIONICS HOLDINGS, INC.

Amended at-the-market offering agreement with H.C. Wainwright to remove $6.75 per share floor, effective June 12, 2023.
Prior ATM sales: 77,594 shares at avg $10.72 for $791,217 net proceeds; $6.67M remains available.
Shareholders approved 2014 Equity Incentive Plan amendment, increasing authorized shares from 2,524,286 to 3,724,286.
All five director nominees elected; advisory say-on-pay passed with ~4.1M For vs 293K Against.
Ratified WithumSmith+Brown as independent auditor for FY2023 with ~7.0M For votes.

item 1.01 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

EKSO BIONICS HOLDINGS, INC. amended Amendment with H.C. Wainwright & Co., LLC (effective 2023-06-12).

Action: amendment
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2023-06-12

Exact text from the filing

On June 12, 2023, Ekso Bionics Holdings, Inc. (the “Company”) entered into an amendment (the “Amendment”) to that certain At the Market Offering Agreement dated as of October 9, 2020 (the “Sales Agreement”), by and between the Company and H.C. Wainwright & Co., LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares of the Company’s common stock, par value $0.001 per share (the “Shares”), in an “at-the-market” offering.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

EKSO BIONICS HOLDINGS, INC. shareholders approved Ratification of appointment of WithumSmith+Brown, PC as independent auditors at the 2023-06-08 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

For Against Abstained Broker Non-votes 7,027,946 152,140 49,764 n/a

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

EKSO BIONICS HOLDINGS, INC. shareholders approved Amendment of 2014 Equity Incentive Plan to increase authorized shares from 2,524,286 to 3,724,286 at the 2023-06-08 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

For Against Abstained Broker Non-votes 3,898,757 551,457 22,272 2,757,364

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

EKSO BIONICS HOLDINGS, INC. shareholders approved Advisory vote on named executive officer compensation at the 2023-06-08 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

For Against Abstained Broker Non-votes 4,111,482 293,055 67,949 2,757,364

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

EKSO BIONICS HOLDINGS, INC. shareholders approved Election of five persons to the Company’s board of directors at the 2023-06-08 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

Scott G. Davis 4,312,949 159,537 2,757,364

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

EKSO BIONICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-070425

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.